IRGQ Knockout SK-OV-3 Polyclonal Cells are a heterogeneous population of SK-OV-3 human ovarian adenocarcinoma cells harboring CRISPR/Cas9-mediated disruption of the endogenous IRGQ gene. As a polyclonal knockout product, this cell mixture contains a variety of loss-of-function alleles generated without single-cell cloning, thus maintaining population diversity. This format is valuable for functional studies where it is desirable to avoid clonal selection artifacts and to better approximate the genetic variability seen in malignant tissues.
SK-OV-3 is an established human ovarian adenocarcinoma cell line derived from the ascitic fluid of a 64-year-old Caucasian female. The cells carry a TP53 mutation typical of high-grade serous ovarian carcinoma and exhibit an epithelial morphology. SK-OV-3 is widely utilized as a pre?clinical model to investigate molecular drivers of ovarian cancer progression, drug resistance, and cellular response to chemotherapeutics such as cisplatin. This background provides a physiologically relevant setting for interrogating autophagy and apoptotic pathways.
IRGQ belongs to the interferon-inducible GTPase family and is transcriptionally activated by type I interferons through JAK-STAT signaling, with STAT1 serving as a key downstream effector of IFNG. The protein physically interacts with the autophagy regulators ATG5, BECN1, and LC3, and it modulates mTOR-AKT signaling upstream of mTORC1, ULK1, and ATG14. Additionally, IRGQ influences apoptosis by targeting BAD and Caspase-3, placing it at an intersection of nutrient-sensing, cell survival, and programmed death pathways.
Knocking out IRGQ in SK-OV-3 cells is predicted to disrupt autophagic flux and dampen mTOR-AKT signaling, thereby sensitizing the cells to nutrient stress and possibly enhancing apoptotic responses. Given that ovarian cancer cells frequently rely on autophagy for survival under hypoxic and nutrient-depleted conditions, this model can expose context-specific vulnerabilities. The polyclonal population reflects the genetic heterogeneity of tumors, making it suited for preclinical studies aimed at evaluating synthetic lethal interactions and therapeutic targeting of autophagy in ovarian adenocarcinoma.
This IRGQ knockout polyclonal cell population supports a wide range of experimental workflows, including autophagy flux measurements by LC3 immunofluorescence and p62 Western blotting, apoptosis assessments via flow cytometric detection of activated Caspase-3, and drug sensitivity testing with cisplatin or mTOR inhibitors. RT?qPCR can verify IRGQ transcript depletion, while xenograft studies allow in vivo evaluation of tumor growth and treatment responses. For additional technical information, please contact Ascent Research.
